An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

NCT02407223 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

356

Enrollment

INDUSTRY

Sponsor class

Stopped This study was stopped because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.

Conditions

Nonradiographic Axial Spondylitis, Ankylosing

Interventions

DRUG: Group 1: Placebo
DRUG: Group 2: Ustekinumab 45 mg
DRUG: Group 3: Ustekinumab 90 mg

Sponsor

Janssen Research & Development, LLC